Long Non-Coding RNA PLAC2 Suppresses the Survival of Gastric Cancer Cells Through Down-Regulating C-Myc

Total Page:16

File Type:pdf, Size:1020Kb

Long Non-Coding RNA PLAC2 Suppresses the Survival of Gastric Cancer Cells Through Down-Regulating C-Myc European Review for Medical and Pharmacological Sciences 2020; 24: 12187-12193 Long non-coding RNA PLAC2 suppresses the survival of gastric cancer cells through down-regulating C-Myc C.-C. WU1, Y. YANG2, F.-F. MAO3, W.-X. GUO2, D. WU1 1Department of Gastrointestinal Surgery, Xinghua People’s Hospital, The Affiliated Hospital of Yangzhou University, Taizhou, China 2Department of Hepatic Surgery VI, Third Affiliated Hospital of Second Military Medical University, Shanghai, China 3Department of Tongji University Cancer Center, Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China Chunchen Wu and Yang Yang contributed equally to this work Abstract. – OBJECTIVE: The aim of this study Introduction was to explore the effects of long non-coding ri- bonucleic acid (lncRNA) placenta-specific pro- Gastric cancer (GC) is the most common tein 2 (PLAC2) on the biological behaviors of highly-invasive malignant tumor in the digestive gastric cancer (GC) cells by regulating the ex- system, whose morbidity and mortality rates are pression of c-Myc gene and its mechanism. 1 PATIENTS AND METHODS: The expression increasing year by year . According to statistics, of PLAC2 in GC tissues and different GC cell there are 35,000 cases of GC deaths in China ev- lines was detected via quantitative Reverse ery year, mostly due to distant metastasis of ad- Transcription-Polymerase Chain Reaction (qRT- vanced GC2. Currently, the specific pathogeny of PCR). The effects of PLAC2 on apoptosis and GC remains unknown, and the median survival cycle, migration, and invasion of GC cells were time of GC patients undergoing convention- detected using flow cytometry, wound healing 3 assay, and transwell assay, respectively. After al drug therapy is less than 15 months . To im- interference in PLAC2 expression, the changes prove the existing diagnosis and treatment of GC, in c-Myc expression were determined through studying the mechanism of GC occurrence and qRT-PCR and Western blotting. metastasis may have a substantial influence on the RESULTS: The expression level of PLAC2 therapeutic strategies in the future, and provide was downregulated in 38 out of 45 cases of GC an effective therapeutic method for GC patients. tissues compared with that in normal gastric Long non-coding ribonucleic acids (lncRNAs) tissues, and it also declined in GC cells. The results of flow cytometry showed that after affect important biological processes of a variety overexpression of PLAC2, the cell cycle was of cells, such as invasion and metastasis of tu- arrested in the G1/G0 phase, and the apoptosis mor cells4,5. HOX tran antisense RNA (HOTAIR) rate was increased. The results of wound heal- is highly expressed in breast tumors, which can ing assay and transwell assay revealed that target specific genomic loci through chroma- both migration and invasion of GC cells were tin repressor proteins, thus promoting metasta- inhibited. After overexpression of PLAC2, the 6 7 mRNA and protein expression levels of c-Myc sis of breast cancer . Fang et al showed that ln- declined. cRNA-p21 associated with hnRNP-K is involved CONCLUSIONS: LncRNA PLAC2 affects the in regulating the transcriptional reaction as a biological behaviors of GC cells by regulating p53-dependent repressor. LncRNA MALAT1 is the expression of c-Myc gene. involved in regulating the cell growth and tumor metastasis, there are many downstream target Key Words: genes, and different activation pathways partici- LncRNA PLAC2, Gastric cancer, Biological behav- 8 iors, c- Myc. pate in the regulation of different behaviors . The above findings suggest that lncRNAs may serve Corresponding Authors: Weixing Guo, MD; e-mail: [email protected] 12187 Duo Wu, MS; e-mail: [email protected] C.-C. Wu, Y. Yang, F.-F. Mao, W.-X. Guo, D. Wu as important regulators of tumorigenesis, but the reagent (Invitrogen, Carlsbad, CA, USA), the RNA regulatory effect of lncRNAs on specific human concentration, and purity were measured using a tumors and their association with tumorigenesis NanoDrop 2000 spectrophotometer, and RNA was have not been fully clarified. reversely transcribed into complementary deoxy- The expression of lncRNA placenta-specif- ribonucleic acid (cDNA) (TaKaRa, Otsu, Shiga, ic protein 2 (PLAC2) is dysregulated in various Japan), followed by cDNA amplification under tumors and it exerts important biological func- the following conditions: pre-denaturation at 95°C tions9,10. Zheng et al11 found that PLAC2 has a for 10 min, denaturation at 95°C for 15 s, and an- downregulated expression in non-small cell lung nealing at 60°C for 32 s for a total of 50 cycles. cancer, which suppresses the tumor growth by Then, the dissolution curve was detected, the Ct adsorbing microRNA-21 (miR-21). Moreover, value of each sample was automatically analyzed PLAC2 induces apoptosis of hepatocellular carci- using the computer system, and the relative expres- noma via upregulating the p53 expression12. How- sion level of lncRNA was calculated using 2-ΔΔCt ever, the expression and function of PLAC2 in GC method. The experiment was repeated for 3 times. have not been reported yet. In the present study, Primers used were shown below: lncRNA PLAC2 it was discovered using in vitro experiments that F 5’-CCATTCCATTCATTTCTCTTTCCTA-3’, PLAC2 was downregulated in GC and inhibited R 5’-GGCGTAGGCGATTGGGGATCG-3’, the formation of malignant phenotype. c-MYC F 5’-ATTTAAGGAGCGGATTTAGC-3’ R 5’-TTTTCGAGTCGAAACACACT-3’, glycer- aldehyde 3-phosphate dehydrogenase (GAPDH) R Patients and Methods 5’-AGCGAGCATCCCCCAAAGTT-3’ F 5’-GGG- CACGAAGGCTCATCATT-3’. Tissue Specimens Tissue specimens were taken from patients un- Plasmid Construction and Transfection dergoing radical gastrectomy in Xinghua People’s The PLAC2 overexpression plasmids were Hospital from January 2016 to December 2017, commercial products synthesized and identified and the patients were definitely diagnosed with by Shanghai Genechem Co., Ltd. (Shanghai, Chi- gastric adenocarcinoma by more than two pathol- na), in which PLAC2 sequences were subcloned ogists and they received no radiotherapy, targeted into pcDNA vectors (pcDNA-PLAC2), with therapy, and immunotherapy before surgery. Af- pcDNA3.1 empty vectors as negative controls. ter excision, tissue specimens were immediately GC cell lines were inoculated into a 6-well plate stored in liquid nitrogen at -180°C for subsequent (5×10 5 cells/well), and they were transfected with experiments. This study was approved by the Eth- pcDNA-PLAC2 and empty vectors using Lipo- ics Committee of Xinghua People’s Hospital and fectamine 2000 (Invitrogen, Carlsbad, CA, USA) patients signed a written informed consent. when 70% of them were fused. The medium was replaced after 6 h, and the cells were collected for Cell Culture qRT-PCR after 48 h. Human GC SGC-7901, AGS, MKN45, and BGC823 cell lines, and normal human gastric Wound Healing Assay mucosal epithelial cell line GES-l were purchased The cells were inoculated into a 24-well plate from the Shanghai Cell Bank of the Chinese Acad- (1×10 4 cells/well). When about 70% of cells were emy of Sciences (Shanghai, China). All cells were fused, they were scratched uniformly along the cultured in the Dulbecco’s Modified Eagle’s Me- diameter of plate using a 20 μL pipette tip perpen- dium (DMEM) or Roswell Park Memorial Insti- dicular to the bottom of plate. The floating cells tute-1640 (RPMI-1640) medium (HyClone, South shed were washed away with phosphate-buffered Logan, UT, USA) containing 10% fetal bovine se- saline (PBS), and fresh medium containing 2% rum (FBS; Gibco, Rockville, MD, USA), strepto- FBS was added. Then, the width of the wound mycin (100 μg/mL), and penicillin (100 U/mL) in was observed and measured at 0 and 36 h, and the an incubator with 5% CO2 and humidity at 37°C. cell migration ability was determined. The assay was repeated for 3 times. Quantitative Reverse Transcription- Polymerase Chain Reaction (qRT-PCR) Transwell Invasion Assay The total RNA was isolated from GC tissue and The transfected cells were cultured till the para-carcinoma normal tissues using the TRIzol logarithmic growth phase, resuspended in the 12188 LncRNA PLAC2 in gastric cancer cells serum-free medium, and added into the upper statistical analyses. The data were expressed as (χ– chamber (1×10 4 cells/well) containing growth ±s), and statistical analysis was performed using medium supplemented by 10% fetal bovine se- Student’s t-test. The association between the ex- rum and growth factor at a normal concentra- pression levels of PLAC2 and c-Myc was detected tion at the bottom. After incubation for 24 h, via Pearson correlation analysis. p<0.05 suggested the cells on the upper side of membrane were the statistically significant difference. removed with Matrigel and the top of membrane was wiped with a cotton swab. Then, the cells on the lower side of membrane were fixed and Results stained with 1% crystal violet dye, followed by photography and observation under an optical Expression of LncRNA PLAC2 microscope. Declined in GC The relative expression level of PLAC2 in 45 Detection of Apoptosis Via Flow cases of GC tissues was detected via qRT-PCR. Cytometry The results revealed that the expression of PLAC2 The transfected cells were collected, washed was downregulated in 38 cases compared with twice with cold PBS, and resuspended in binding that in para-carcinoma tissues (Figure 1A). To buffer, followed by staining using the Annexin study the biological function of PLAC2 in GC V- fluorescein isothiocyanate (FITC) apoptosis cells, its relative expression level in GC cells was assay kit (BD Bioscience, Franklin Lakes, NJ, detected via qRT-PCR. The results showed that USA) at room temperature in the dark for 30 min. the expression of PLAC2 was downregulated The apoptosis rate was measured using a flow cy- (Figure 1B). Then, PLAC2 overexpression vectors tometer (Becton Dickinson, Franklin Lakes, NJ, were synthesized and transiently transfected into USA) within 1 h.
Recommended publications
  • Aberrant Methylation Underlies Insulin Gene Expression in Human Insulinoma
    ARTICLE https://doi.org/10.1038/s41467-020-18839-1 OPEN Aberrant methylation underlies insulin gene expression in human insulinoma Esra Karakose1,6, Huan Wang 2,6, William Inabnet1, Rajesh V. Thakker 3, Steven Libutti4, Gustavo Fernandez-Ranvier 1, Hyunsuk Suh1, Mark Stevenson 3, Yayoi Kinoshita1, Michael Donovan1, Yevgeniy Antipin1,2, Yan Li5, Xiaoxiao Liu 5, Fulai Jin 5, Peng Wang 1, Andrew Uzilov 1,2, ✉ Carmen Argmann 1, Eric E. Schadt 1,2, Andrew F. Stewart 1,7 , Donald K. Scott 1,7 & Luca Lambertini 1,6 1234567890():,; Human insulinomas are rare, benign, slowly proliferating, insulin-producing beta cell tumors that provide a molecular “recipe” or “roadmap” for pathways that control human beta cell regeneration. An earlier study revealed abnormal methylation in the imprinted p15.5-p15.4 region of chromosome 11, known to be abnormally methylated in another disorder of expanded beta cell mass and function: the focal variant of congenital hyperinsulinism. Here, we compare deep DNA methylome sequencing on 19 human insulinomas, and five sets of normal beta cells. We find a remarkably consistent, abnormal methylation pattern in insu- linomas. The findings suggest that abnormal insulin (INS) promoter methylation and altered transcription factor expression create alternative drivers of INS expression, replacing cano- nical PDX1-driven beta cell specification with a pathological, looping, distal enhancer-based form of transcriptional regulation. Finally, NFaT transcription factors, rather than the cano- nical PDX1 enhancer complex, are predicted to drive INS transactivation. 1 From the Diabetes Obesity and Metabolism Institute, The Department of Surgery, The Department of Pathology, The Department of Genetics and Genomics Sciences and The Institute for Genomics and Multiscale Biology, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
    [Show full text]
  • DNA Methylation Signatures of Early Childhood Malnutrition Associated with Impairments in Attention and Cognition
    Biological Archival Report Psychiatry DNA Methylation Signatures of Early Childhood Malnutrition Associated With Impairments in Attention and Cognition Cyril J. Peter, Laura K. Fischer, Marija Kundakovic, Paras Garg, Mira Jakovcevski, Aslihan Dincer, Ana C. Amaral, Edward I. Ginns, Marzena Galdzicka, Cyralene P. Bryce, Chana Ratner, Deborah P. Waber, David Mokler, Gayle Medford, Frances A. Champagne, Douglas L. Rosene, Jill A. McGaughy, Andrew J. Sharp, Janina R. Galler, and Schahram Akbarian ABSTRACT BACKGROUND: Early childhood malnutrition affects 113 million children worldwide, impacting health and increasing vulnerability for cognitive and behavioral disorders later in life. Molecular signatures after childhood malnutrition, including the potential for intergenerational transmission, remain unexplored. METHODS: We surveyed blood DNA methylomes (483,000 individual CpG sites) in 168 subjects across two generations, including 50 generation 1 individuals hospitalized during the first year of life for moderate to severe protein-energy malnutrition, then followed up to 48 years in the Barbados Nutrition Study. Attention deficits and cognitive performance were evaluated with the Connors Adult Attention Rating Scale and Wechsler Abbreviated Scale of Intelligence. Expression of nutrition-sensitive genes was explored by quantitative reverse transcriptase polymerase chain reaction in rat prefrontal cortex. RESULTS: We identified 134 nutrition-sensitive, differentially methylated genomic regions, with most (87%) specific for generation 1. Multiple neuropsychiatric risk genes, including COMT, IFNG, MIR200B, SYNGAP1, and VIPR2 showed associations of specific methyl-CpGs with attention and IQ. IFNG expression was decreased in prefrontal cortex of rats showing attention deficits after developmental malnutrition. CONCLUSIONS: Early childhood malnutrition entails long-lasting epigenetic signatures associated with liability for attention and cognition, and limited potential for intergenerational transmission.
    [Show full text]
  • Universidade Estadual De Campinas Instituto De Biologia
    UNIVERSIDADE ESTADUAL DE CAMPINAS INSTITUTO DE BIOLOGIA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA CAMPINAS 2016 1 VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA Dissertação apresentada ao Instituto de Biologia da Universidade Estadual de Campinas como parte dos requisitos exigidos para a obtenção do Título de Mestra em Biologia Funcional e Molecular na área de concentração de Bioquímica. Dissertation presented to the Institute of Biology of the University of Campinas in partial fulfillment of the requirements for the degree of Master in Functional and Molecular Biology, in the area of Biochemistry. ESTE ARQUIVO DIGITAL CORRESPONDE À VERSÃO FINAL DA DISSERTAÇÃO DEFENDIDA PELA ALUNA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA E ORIENTADA PELO DANIEL MARTINS-DE-SOUZA. Orientador: Daniel Martins-de-Souza CAMPINAS 2016 2 Agência(s) de fomento e nº(s) de processo(s): CNPq, 151787/2F2014-0 Ficha catalográfica Universidade Estadual de Campinas Biblioteca do Instituto de Biologia Mara Janaina de Oliveira - CRB 8/6972 Saia-Cereda, Verônica Aparecida Monteiro, 1988- Sa21p O proteoma do corpo caloso da esquizofrenia / Verônica Aparecida Monteiro Saia Cereda. – Campinas, SP : [s.n.], 2016. Orientador: Daniel Martins de Souza. Dissertação (mestrado) – Universidade Estadual de Campinas, Instituto de Biologia. 1. Esquizofrenia. 2. Espectrometria de massas. 3. Corpo caloso.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Aïda Homs Raubert
    Epigenetic alterations in autism spectrum disorders (ASD) Aïda Homs Raubert DOCTORAL THESIS UPF 2015 THESIS SUPERVISORS Prof. Luis A. Pérez Jurado Dra. Ivon Cuscó Martí DEPARTAMENT DE CIÈNCIES EXPERIMENTALS I DE LA SALUT Als meus pares, a l’Alexandra a l’Agustí i als bessons que vindran iii ACKNOWLEDGEMENTS Aquesta no és nomes la meva tesi, en ella han contribuït moltes persones, tant de l’entorn del parc de recerca, de terres lleidatanes, Berguedanes i fins i tot de l’altra banda de l’Atlàntic. Primer, volia agrair als directors de tesi, al Prof. Luis Pérez Jurado i a la Dra. Ivon Cuscó, tot el temps dedicat a revisar i corregir els raonaments i les paraules en aquesta tesi, ja que sempre han tingut la porta oberta per atendre qualsevol dubte. També per haver-me ensenyat una metodologia, un rigor i un llenguatge científic, on l’entrenament és necessari per assolir els conceptes per la recerca en concret, i pel món de la ciència i la genètica. Gràcies per la dedicació, la paciencia, la feina i energia dipositada. No hagués arribat al mateix port si al laboratori no m’hagués trobat amb persones que m’inspiren. Primer de tot, a les nenes: a la Gabi, la companya de vaixell fins i tot el dia de dipositar la tesi, perquè sobretot ens hem sabut acompanyar i entendre malgrat tenir altres maneres de funcionar, gràcies. També a la Marta i la Cristina, que amb la seva honestedat i bona fe, omplen el laboratori de bones energies, gràcies per ser-hi en tot moment.
    [Show full text]
  • Mining Novel Candidate Imprinted Genes Using Genome-Wide Methylation Screening and Literature Review
    epigenomes Article Mining Novel Candidate Imprinted Genes Using Genome-Wide Methylation Screening and Literature Review Adriano Bonaldi 1, André Kashiwabara 2, Érica S. de Araújo 3, Lygia V. Pereira 1, Alexandre R. Paschoal 2 ID , Mayra B. Andozia 1, Darine Villela 1, Maria P. Rivas 1 ID , Claudia K. Suemoto 4,5, Carlos A. Pasqualucci 5,6, Lea T. Grinberg 5,7, Helena Brentani 8 ID , Silvya S. Maria-Engler 9, Dirce M. Carraro 3, Angela M. Vianna-Morgante 1, Carla Rosenberg 1, Luciana R. Vasques 1,† and Ana Krepischi 1,*,† ID 1 Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, Rua do Matão 277, 05508-090 São Paulo, SP, Brazil; [email protected] (A.B.); [email protected] (L.V.P.); [email protected] (M.B.A.); [email protected] (D.V.); [email protected] (M.P.R.); [email protected] (A.M.V.-M.); [email protected] (C.R.); [email protected] (L.R.V.) 2 Department of Computation, Federal University of Technology-Paraná, Avenida Alberto Carazzai, 1640, 86300-000 Cornélio Procópio, PR, Brazil; [email protected] (A.K.); [email protected] (A.R.P.) 3 International Center for Research, A. C. Camargo Cancer Center, Rua Taguá, 440, 01508-010 São Paulo, SP, Brazil; [email protected] (É.S.d.A.); [email protected] (D.M.C.) 4 Division of Geriatrics, University of São Paulo Medical School, Av. Dr. Arnaldo, 455, 01246-903 São Paulo, SP, Brazil; [email protected] 5 Brazilian Aging Brain Study Group-LIM22, Department of Pathology, University of São Paulo Medical School, Av.
    [Show full text]
  • Characterization of Whole-Genome Autosomal
    Singmann et al. Epigenetics & Chromatin (2015) 8:43 DOI 10.1186/s13072-015-0035-3 RESEARCH Open Access Characterization of whole‑genome autosomal differences of DNA methylation between men and women Paula Singmann1,2*, Doron Shem‑Tov3, Simone Wahl1,2,4, Harald Grallert1,2,4, Giovanni Fiorito5,6, So‑Youn Shin7,8, Katharina Schramm9,10, Petra Wolf9,10, Sonja Kunze1,2, Yael Baran3, Simonetta Guarrera5,6, Paolo Vineis5,11, Vittorio Krogh12, Salvatore Panico13, Rosario Tumino14, Anja Kretschmer1,2, Christian Gieger1,2, Annette Peters2,4, Holger Prokisch9,10, Caroline L. Relton7,8, Giuseppe Matullo5,6, Thomas Illig1,15,16, Melanie Waldenberger1,2 and Eran Halperin3,17,18* Abstract Background: Disease risk and incidence between males and females reveal differences, and sex is an important component of any investigation of the determinants of phenotypes or disease etiology. Further striking differences between men and women are known, for instance, at the metabolic level. The extent to which men and women vary at the level of the epigenome, however, is not well documented. DNA methylation is the best known epigenetic mechanism to date. Results: In order to shed light on epigenetic differences, we compared autosomal DNA methylation levels between men and women in blood in a large prospective European cohort of 1799 subjects, and replicated our findings in three independent European cohorts. We identified and validated 1184 CpG sites to be differentially methylated between men and women and observed that these CpG sites were distributed across all autosomes. We showed that some of the differentially methylated loci also exhibit differential gene expression between men and women.
    [Show full text]
  • WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/063579 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 5 November 20 12 (05 .11.20 12) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/579,530 22 December 201 1 (22. 12.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: AVEO PHARMACEUTICALS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 75 Sidney Street, Fourth Floor, Cambridge, MA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 02139 (US).
    [Show full text]
  • Global Network Random Walk for Predicting Potential Human Lncrna
    www.nature.com/scientificreports OPEN Global network random walk for predicting potential human lncRNA-disease associations Received: 27 March 2017 Changlong Gu1, Bo Liao1, Xiaoying Li1, Lijun Cai1, Zejun Li1,2, Keqin Li3 & Jialiang Yang 4 Accepted: 14 September 2017 There is more and more evidence that the mutation and dysregulation of long non-coding RNA Published: xx xx xxxx (lncRNA) are associated with numerous diseases, including cancers. However, experimental methods to identify associations between lncRNAs and diseases are expensive and time-consuming. Efective computational approaches to identify disease-related lncRNAs are in high demand; and would beneft the detection of lncRNA biomarkers for disease diagnosis, treatment, and prevention. In light of some limitations of existing computational methods, we developed a global network random walk model for predicting lncRNA-disease associations (GrwLDA) to reveal the potential associations between lncRNAs and diseases. GrwLDA is a universal network-based method and does not require negative samples. This method can be applied to a disease with no known associated lncRNA (isolated disease) and to lncRNA with no known associated disease (novel lncRNA). The leave-one-out cross validation (LOOCV) method was implemented to evaluate the predicted performance of GrwLDA. As a result, GrwLDA obtained reliable AUCs of 0.9449, 0.8562, and 0.8374 for overall, novel lncRNA and isolated disease prediction, respectively, signifcantly outperforming previous methods. Case studies of colon, gastric, and kidney cancers were also implemented, and the top 5 disease-lncRNA associations were reported for each disease. Interestingly, 13 (out of the 15) associations were confrmed by literature mining. A non-coding RNA (ncRNA) is an RNA molecule that is not translated into protein.
    [Show full text]
  • SUPPLEMENTARY INFORMATION Genome-Wide Association Study
    SUPPLEMENTARY INFORMATION Genome-wide association study and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes Franceschini, Giambartolomei et al. Supplementary Note 1 Study Descriptions This study includes data from the CHARGE and UCLEB Consortia. For all studies, each participant provided written informed consent. The Institutional Review Board at the parent institution for each respective study approved the study protocols. CHARGE Consortium The Aging Gene-Environment Susceptibility-Reykjavik Study (AGES) cohort originally comprised a random sample of 30,795 men and women born in 1907–1935 and living in Reykjavik in 1967.1 A total of 19,381 individuals attended, resulting in 71% recruitment rate. The study sample was divided into six groups by birth year and birth date within month. One group was designated for longitudinal follow-up and was examined in all stages. One group was designated a control group and was not included in examinations until 1991. Other groups were invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-Reykjavik study re-examined 5764 survivors of the original cohort who had participated before in the Reykjavik Study. The AGES Reykjavik Study GWAS was approved by the National Bioethics Committee (00-063-V8+1) and the Data Protection Authority. The Atherosclerosis Risk in Communities Study (ARIC) is a multi-center prospective investigation of atherosclerotic disease in a predominantly bi-racial population. 2 Men and women aged 45-64 years at baseline were recruited from 4 communities: Forsyth County, North Carolina; Jackson, Mississippi; suburban areas of Minneapolis, Minnesota; and Washington County, Maryland.
    [Show full text]
  • Tissue-Specific Co-Expression of Long Non-Coding and Coding Rnas Associated with Breast Cancer
    Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Wu, Wenting, Erin K. Wagner, Yangyang Hao, Xi Rao, Hongji Dai, Jiali Han, Jinhui Chen, Anna Maria V. Storniolo, Yunlong Liu, and Chunyan He. 2016. “Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer.” Scientific Reports 6 (1): 32731. doi:10.1038/srep32731. http://dx.doi.org/10.1038/ srep32731. Published Version doi:10.1038/srep32731 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407754 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA www.nature.com/scientificreports OPEN Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer Received: 12 May 2016 Wenting Wu1,*, Erin K. Wagner1,*, Yangyang Hao2, Xi Rao2, Hongji Dai1,3, Jiali Han1,4,5, Accepted: 12 August 2016 Jinhui Chen6, Anna Maria V. Storniolo7, Yunlong Liu2,8 & Chunyan He1,5,8 Published: 06 September 2016 Inference of the biological roles of lncRNAs in breast cancer development remains a challenge. Here, we analyzed RNA-seq data in tumor and normal breast tissue samples from 18 breast cancer patients and 18 healthy controls and constructed a functional lncRNA-mRNA co-expression network. We revealed two distinctive co-expression patterns associated with breast cancer, reflecting different underlying regulatory mechanisms: (1) 516 pairs of lncRNA-mRNAs have differential co-expression pattern, in which the correlation between lncRNA and mRNA expression differs in tumor and normal breast tissue; (2) 291 pairs have dose-response co-expression pattern, in which the correlation is similar, but the expression level of lncRNA or mRNA differs in the two tissue types.
    [Show full text]